Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
Di Landro A., Naldi L., Marchesi L.
Department of Dermatology, University of Milano-Bicocca Ospedali Riuniti, Bergamo, Italy
Imiquimod 5% cream has been used effectively to treat basal cell carcinomas (BCCs). The purpose of this study was to examine the effectiveness and tolerability of Imiquimod 5% cream in treating superficial non-facial BCCs in a patient with basal cell nevus syndrome or Gorlin's syndrome and to follow the patient over time for any signs of relapse. Five superficial BCCs in the mammarian region of a woman suffering psychologically due to multiple scars resulting from many BCC removals, were treated for 18 weeks with a once-a-day application of Imiquimod 5% cream. A biopsy was performed before and after the treatment. The 5 BCCs regressed completely without any sign of histological persistence. Topical therapy caused irritation in the first weeks of treatment, which resolved after a reduction in the number of applications. A three-year follow up confirmed that no relapse had occurred and no scarring was present at the sites of treatment; only the appearance of a new small papular lesion was noted slightly above the treated area. Imiquimod 5% cream can be considered an effective treatment with good cosmetic results and absence of long term recurrence for multiple BCCs in basal cell nevus syndrome.
language: English, Italian